ReviewDermatology online journal2025
Silver sulfadiazine in modern dermatology.
Review in Dermatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silver sulfadiazine, a topical antimicrobial that releases silver ions to disrupt bacterial cell membranes, is primarily used for second- and third-degree burns owing to its broad-spectrum activity against bacteria, fungi, and certain viruses. Beyond burns, silver sulfadiazine can be used off-label for conditions such as diabetic and pressure ulcers, atopic dermatitis, and radiation dermatitis. The literature suggests it may reduce bacterial load, accelerate healing, and address challenges such as multidrug-resistant Staphylococcus aureus. Rare side effects, including localized reactions and systemic toxicity with extensive use, necessitate cautious application, especially in vulnerable populations. Despite these limitations, silver sulfadiazine remains a cornerstone of dermatological wound care. Continued research is needed to optimize its use alongside emerging therapies.
Indexed as
Identifiers
41725469What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.